Table 1.
Demographic and clinical characteristics at baseline
| All patients (N = 431) | BEV + CP (n = 231) | CP (n = 200) | p valuea | |
|---|---|---|---|---|
| Age in years | 64.6 ± 9.8 | 65.5 ± 67.0 | 63.6 ± 63.0 | 0.045 |
| Age group, years | ||||
| 18–64 | 200 (46.4) | 94 (40.7) | 106 (53.0) | |
| 65–69 | 86 (20.0) | 54 (23.4) | 32 (16.0) | |
| 70–74 | 75 (17.4) | 45 (19.5) | 30 (15.0) | |
| ≥75 | 70 (16.2) | 38 (16.5) | 32 (16.0) | |
| Male | 239 (55.5) | 126 (54.5) | 113 (56.5) | 0.684 |
| Race/ethnicity | 0.010 | |||
| Caucasian | 236 (54.8) | 127 (55.0) | 109 (54.5) | |
| African American | 32 (7.4) | 11 (4.8) | 21 (10.5) | |
| Asian | 2 (0.5) | 2 (0.9) | 0 (0.0) | |
| Hispanic | 2 (0.5) | 0 (0.0) | 2 (1.0) | |
| Other | 4 (0.9) | 0 (0.0) | 4 (2.0) | |
| Missing | 155 (36.0) | 91 (39.4) | 64 (32.0) | |
| Patient insurance | 0.002 | |||
| Medicaid | 22 (5.1) | 6 (2.6) | 16 (8.0) | |
| Medicare | 186 (43.2) | 114 (49.4) | 72 (36.0) | |
| Other | 5 (1.2) | 0 (0.0) | 5 (2.5) | |
| Private | 168 (39.0) | 85 (36.8) | 83 (41.5) | |
| Missing | 50 (11.6) | 26 (11.3) | 24 (12.0) | |
| Geographic region of practice | 0.881 | |||
| Midwest | 91 (21.1) | 47 (20.3) | 44 (22.0) | |
| Northeast | 30 (7.0) | 15 (6.5) | 15 (7.5) | |
| South | 283 (65.7) | 153 (66.2) | 130 (65.0) | |
| West | 27 (6.3) | 16 (6.9) | 11 (5.5) | |
| Location of metastases | ||||
| Adrenal glands | 77 (17.9) | 37 (16.0) | 40 (20.0) | 0.282 |
| Bone | 201 (46.6) | 126 (54.5) | 75 (37.5) | <0.001 |
| Brain | 96 (22.3) | 25 (10.8) | 71 (35.5) | <0.001 |
| Contralateral lung | 64 (14.8) | 37 (16.0) | 27 (13.5) | 0.464 |
| Liver | 81 (18.8) | 49 (21.2) | 32 (16.0) | 0.167 |
| Lymph nodes | 232 (53.8) | 116 (50.2) | 116 (58.0) | 0.106 |
| Pericardium | 21 (4.9) | 8 (3.5) | 13 (6.5) | 0.144 |
| Pleural surface | 90 (20.9) | 54 (23.4) | 36 (18.0) | 0.171 |
| Other | 19 (4.4) | 5 (2.2) | 14 (7.0) | 0.015 |
| ECOG PS | 0.348 | |||
| 0 | 99 (23.0) | 52 (22.5) | 47 (23.5) | |
| 1 | 159 (36.9) | 95 (41.1) | 64 (32.0) | |
| 2 | 50 (11.6) | 24 (10.4) | 26 (13.0) | |
| ≥3 | 7 (1.6) | 4 (1.7) | 3 (1.5) | |
| Unknown | 116 (26.9) | 56 (24.2) | 60 (30.0) | |
| Smoking status | 0.327 | |||
| Current smoker | 150 (34.8) | 80 (34.6) | 70 (35.0) | |
| Prior smoker (quit) | 214 (49.7) | 109 (47.2) | 105 (52.5) | |
| Never smoked | 47 (10.9) | 28 (12.1) | 19 (9.5) | |
| Unknown | 20 (4.6) | 14 (6.1) | 6 (3.0) | |
| BMI | 0.344 | |||
| Underweight | 22 (5.1) | 8 (3.5) | 14 (7.0) | |
| Normal | 168 (39.0) | 88 (38.1) | 80 (40.0) | |
| Overweight | 144 (33.4) | 80 (34.6) | 64 (32.0) | |
| Obese | 97 (22.5) | 55 (23.8) | 42 (21.0) | |
| Charlson comorbidity index score | 6.7 ± 0.9 | 6.7 ± 0.8 | 6.7 ± 1.1 | 0.760 |
| Comorbid conditions | ||||
| Diabetes without end-organ damage | 65 (15.1) | 34 (14.7) | 31 (15.5) | 0.821 |
| Hypertension | 203 (47.1) | 105 (45.5) | 98 (49.0) | 0.462 |
| COPD | 124 (28.8) | 70 (30.3) | 54 (27.0) | 0.450 |
| Congestive heart failure | 9 (2.1) | 5 (2.2) | 4 (2.0) | 1.000 |
| Renal insufficiency/failure | 10 (2.3) | 3 (1.3) | 7 (3.5) | 0.130 |
| Anemia | 10 (2.3) | 1 (0.4) | 9 (4.5) | 0.007 |
| Thrombocytopenia | 5 (1.2) | 3 (1.3) | 2 (1.0) | 1.000 |
| History of myocardial infarction | 22 (5.1) | 13 (5.6) | 9 (4.5) | 0.596 |
| History of stroke/TIA | 10 (2.3) | 7 (3.0) | 3 (1.5) | 0.351 |
| History of bleeding events, serious hemorrhage, recent hemoptysis | 29 (6.7) | 9 (3.9) | 20 (10.0) | 0.012 |
| Cerebrovascular, valvular disease | 7 (1.6) | 3 (1.3) | 4 (2.0) | 0.709 |
| Connective tissue disease, rheumatologic disorders | 10 (2.3) | 6 (2.6) | 4 (2.0) | 0.758 |
| Peripheral vascular disease | 18 (4.2) | 6 (2.6) | 12 (6.0) | 0.078 |
| Ulcer disease | 5 (1.2) | 1 (0.4) | 4 (2.0) | 0.188 |
| Weight loss | 89 (20.6) | 33 (14.3) | 56 (28.0) | <0.001 |
| Cardiovascular disease | 76 (17.6) | 45 (19.5) | 31 (15.5) | 0.280 |
| Venous thromboembolism | 28 (6.5) | 8 (3.5) | 20 (10.0) | 0.006 |
| Hypercholesterolemia | 115 (26.7) | 54 (23.4) | 61 (30.5) | 0.095 |
Data are presented as n (%) or mean ± standard deviation
BEV bevacizumab, BMI body mass index, COPD chronic obstructive pulmonary disease, CP carboplatin + paclitaxel, ECOG Eastern Cooperative Oncology Group, PS performance status, TIA transient ischemic attack
a p values ≤ 0.05 were bolded and considered statistically significant